Plus   Neg

Atara To Suspend Development Of PINTA 745 As Trial Fails To Meet Primary Goal

Atara Biotherapeutics, Inc. (ATRA) Monday said its Phase 2 proof-of-concept clinical trial for PINTA 745 for the treatment of protein energy wasting or PEW in patients with end stage renal disease or ESRD did not meet its primary endpoint.

The primary endpoint is defined as the percent change from baseline in Lean Body Mass as measured by Dual Energy X-Ray Absorptiometry at week 12 following weekly treatment with PINTA 745.

PINTA 745 also did not improve physical function, measures of glycemic control and markers of inflammation. There were no treatment related serious adverse events observed in the trial.

Atara Bio will now suspend further development of PINTA 745. To date, third-party direct costs for the development of PINTA 745 from inception through the third quarter of 2015 were about $10 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year. Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow.
Follow RTT